Biocon Rallies 5% On Novel Therapy Launch For Hepatitis C

Posted By:
Subscribe to GoodReturns

Shares in Biocon surged 5.70 per cent after the company introduced an advanced novel therapy CIMIVIR-L for the treatment of Hepatitis C in India.

The stock was last trading higher by 5.70 per cent on the NSE at Rs 567. "The introduction of CIMIVIR-L will strengthen Biocon's current portfolio of verilogy products," the company said in a release to the bourses.

Biocon Rallies 5% On Novel Therapy Launch For Hepatitis C
CIMIVIR-L, a once-a-day oral therapy, will offer a convenient, effective and safe alternative to people infected with the Hepatitis-C virus (HCV).

"It is estimated that nearly one lakh people die annually in India from HCV infection and co-morbidities. CIMIVIR-L is indicated for Hepatitis-C Genotype 1 patients who account for ~25% of the total estimated HCV patient population of 18 million in the country," the company said in a release.

Read more about: biocon
Story first published: Thursday, December 24, 2015, 11:46 [IST]
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'


Get Latest News alerts from Goodreturns